Johnson & Johnson (NYSE:JNJ) Shares Acquired by Investment House LLC

Posted by Defense World Staff on May 11th, 2023

Investment House LLC boosted its position in Johnson & Johnson (NYSE:JNJ – Get Rating) by 2.2% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 91,899 shares of the company’s stock after purchasing an additional 1,945 shares during the quarter. Johnson & Johnson comprises about 1.5% of Investment House LLC’s holdings, making the stock its 20th largest position. Investment House LLC’s holdings in Johnson & Johnson were worth $16,234,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in JNJ. Glassy Mountain Advisors Inc. bought a new stake in Johnson & Johnson in the fourth quarter valued at about $35,000. Retirement Financial Solutions LLC acquired a new position in shares of Johnson & Johnson during the fourth quarter worth approximately $40,000. TD Capital Management LLC bought a new position in Johnson & Johnson in the 3rd quarter valued at about $48,000. VitalStone Financial LLC acquired a new position in shares of Johnson & Johnson during the fourth quarter valued at approximately $52,000. Finally, Iron Horse Wealth Management LLC lifted its holdings in shares of Johnson & Johnson by 112.8% in the fourth quarter. Iron Horse Wealth Management LLC now owns 300 shares of the company’s stock valued at $53,000 after buying an additional 159 shares during the period. 67.94% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of brokerages recently issued reports on JNJ. Atlantic Securities decreased their target price on Johnson & Johnson from $168.00 to $167.00 and set a “neutral” rating on the stock in a report on Wednesday, April 19th. Piper Sandler lowered their price target on Johnson & Johnson from $55.00 to $52.00 in a report on Monday, February 6th. Guggenheim assumed coverage on Johnson & Johnson in a research note on Tuesday, February 28th. They issued a “neutral” rating and a $161.00 price objective for the company. Credit Suisse Group lifted their target price on shares of Johnson & Johnson from $168.00 to $170.00 in a research note on Friday, May 5th. Finally, StockNews.com assumed coverage on Johnson & Johnson in a research report on Thursday, March 16th. They set a “strong-buy” rating for the company. Seven research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, Johnson & Johnson presently has an average rating of “Moderate Buy” and a consensus target price of $173.00.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, insider James D. Swanson sold 1,062 shares of the business’s stock in a transaction that occurred on Monday, March 6th. The shares were sold at an average price of $154.66, for a total transaction of $164,248.92. Following the completion of the transaction, the insider now directly owns 9,215 shares in the company, valued at $1,425,191.90. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 0.20% of the company’s stock.

Johnson & Johnson Stock Performance

Shares of JNJ opened at $161.65 on Thursday. The firm has a fifty day simple moving average of $158.80 and a 200 day simple moving average of $166.87. The company has a current ratio of 1.07, a quick ratio of 0.85 and a debt-to-equity ratio of 0.49. Johnson & Johnson has a 12 month low of $150.11 and a 12 month high of $183.35. The stock has a market capitalization of $420.08 billion, a price-to-earnings ratio of 33.82, a PEG ratio of 2.77 and a beta of 0.53.

Johnson & Johnson (NYSE:JNJ – Get Rating) last issued its earnings results on Tuesday, April 18th. The company reported $2.68 EPS for the quarter, topping the consensus estimate of $2.51 by $0.17. Johnson & Johnson had a return on equity of 36.13% and a net margin of 13.22%. The company had revenue of $24.75 billion during the quarter, compared to the consensus estimate of $23.61 billion. During the same period in the previous year, the company posted $2.67 EPS. The firm’s revenue for the quarter was up 5.6% compared to the same quarter last year. Research analysts forecast that Johnson & Johnson will post 10.66 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 6th. Shareholders of record on Tuesday, May 23rd will be issued a $1.19 dividend. The ex-dividend date of this dividend is Monday, May 22nd. This represents a $4.76 dividend on an annualized basis and a yield of 2.94%. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.13. Johnson & Johnson’s payout ratio is currently 94.56%.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.